Pro-Life Group Threatens to Sue FDA Over Abortion Pill's Environmental Risks

Students for Life of America (SFLA), a prominent anti-abortion organization, has issued a formal notice of intent to sue the Food and Drug Administration (FDA). The group accuses the agency of neglecting to perform necessary environmental testing on the abortion drug mifepristone, citing potential risks to waterways and wildlife.

The notice, filed on Thursday, comes just before Dr. Heidi Overton's scheduled confirmation hearing to lead the FDA. SFLA contends that when the FDA approved mifepristone in 2000, it did not consult with relevant wildlife protection agencies regarding the drug's potential impact on federally protected species, an alleged violation of the Endangered Species Act.

"We expect these environmental concerns to be taken seriously. I know Dr. Overton is aware of these concerns. Or we expect to see the Trump FDA in court. That's where this will end," SFLA President Kristan Hawkins stated in an interview.

SFLA has given the FDA 60 days to respond to the notice before a lawsuit is initiated. The organization had previously filed 11 citizen petitions urging the FDA to address these environmental concerns. In January 2025, the FDA rejected SFLA's argument, asserting it was not legally required to consult with the U.S. Fish and Wildlife Service or the National Marine Fisheries Service prior to approving mifepristone.

The SFLA's notice references six studies, including a recent paper in Issues in Law & Medicine. This paper reported anti-progesterone activity in water samples from three U.S. cities. SFLA argues these findings suggest the drug may pose environmental risks that warrant further federal review, positing that the drug has entered the U.S. water supply.

However, the referenced study did not directly detect mifepristone in water samples but rather looked for substances that block progesterone. The study's researchers noted that other compounds could potentially produce similar results, and direct detection of mifepristone would typically require specific analytical chemistry techniques.

Hawkins emphasized that the legal challenge is primarily based on the FDA's alleged failure in 2000 to adhere to existing legal requirements. "This should be something that unites all Americans, regardless of how you feel about the violence of abortion. I certainly am pro-life, I wanna see abortion ended. But we all want clean drinking water," she said.

With new leadership expected at the FDA, SFLA aims to bring these environmental concerns to the forefront. "Today, Dr. Heidi Overton will be at the U.S. Senate," Hawkins noted. "And we want to be very clear that when she gets to her desk, when she get confirmed and she sits down, the first thing she sees on her desk is our notice to intent to sue."